BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11506496)

  • 1. Frequency of PSA-mRNA-bearing cells in the peripheral blood of patients after prostate biopsy.
    Hara N; Kasahara T; Kawasaki T; Bilim V; Tomita Y; Obara K; Takahashi K
    Br J Cancer; 2001 Aug; 85(4):557-62. PubMed ID: 11506496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases.
    Thiounn N; Saporta F; Flam TA; Pages F; Zerbib M; Vieillefond A; Martin E; Debré B; Chevillard S
    Urology; 1997 Aug; 50(2):245-50. PubMed ID: 9255296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer.
    Hara N; Kasahara T; Kawasaki T; Bilim V; Obara K; Takahashi K; Tomita Y
    Clin Cancer Res; 2002 Jun; 8(6):1794-9. PubMed ID: 12060619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages.
    Corey E; Arfman EW; Oswin MM; Melchior SW; Tindall DJ; Young CY; Ellis WJ; Vessella RL
    Urology; 1997 Aug; 50(2):184-8. PubMed ID: 9255285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
    Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
    Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
    Pfitzenmaier J; Ellis WJ; Hawley S; Arfman EW; Klein JR; Lange PH; Vessella RL
    Urol Oncol; 2007; 25(3):214-20. PubMed ID: 17483018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of urine DD3/PSA mRNA ratio by duplex TaqMan RT-PCR assay and evolution of its primary application].
    Chen FP; Chen LL; Shen M; Chen W; Tao ZH; Wu XL; Hu YP; Li CD; Chen ZG; Chen XD
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):261-4. PubMed ID: 18361839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of prostate-derived single cells and cell clusters from human peripheral blood.
    Brandt B; Junker R; Griwatz C; Heidl S; Brinkmann O; Semjonow A; Assmann G; Zänker KS
    Cancer Res; 1996 Oct; 56(20):4556-61. PubMed ID: 8840959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer.
    Elkord E; Rowbottom AW; Kynaston H; Williams PE
    Clin Immunol; 2006 Jul; 120(1):91-8. PubMed ID: 16458609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
    Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F
    BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.
    Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM
    Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma.
    Ghossein RA; Rosai J; Scher HI; Seiden M; Zhang ZF; Sun M; Chang G; Berlane K; Krithivas K; Kantoff PW
    Urology; 1997 Jul; 50(1):100-5. PubMed ID: 9218026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Quantitative detection of differential display code 3 mRNA in peripheral blood of patients with prostate cancer].
    Weng ZL; Yu KY; Mao XL; Tao ZH; Chen XD; Wu XL; Hu YP; Wang SQ; Li CD; Chen ZG
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(41):2911-5. PubMed ID: 17288789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of prostatic cancer screening in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities.
    Orihuela E; Kocurek JN; Warren MM
    Arch Esp Urol; 1997 Sep; 50(7):821-4. PubMed ID: 9350090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of lateral biopsy specimens during transrectal ultrasound-guided prostate biopsies in Japanese men.
    Shigemura K; Arakawa S; Yamanaka K; Kataoka N; Yuien K; Fujisawa M
    Int J Urol; 2007 Oct; 14(10):935-8. PubMed ID: 17880293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.